Xeris Pharmaceuticals Inc (NASDAQ:XERS) — Market Cap & Net Worth
Market Cap & Net Worth: Xeris Pharmaceuticals Inc (XERS)
Xeris Pharmaceuticals Inc (NASDAQ:XERS) has a market capitalization of $1.04 Billion ($1.04 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8947 globally and #2403 in its home market, demonstrating a 5.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xeris Pharmaceuticals Inc's stock price $6.28 by its total outstanding shares 172431290 (172.43 Million). Analyse Xeris Pharmaceuticals Inc cash flow conversion to see how efficiently the company converts income to cash.
Xeris Pharmaceuticals Inc Market Cap History: 2018 to 2026
Xeris Pharmaceuticals Inc's market capitalization history from 2018 to 2026. Data shows change from $2.93 Billion to $1.08 Billion (-13.81% CAGR).
Index Memberships
Xeris Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #242 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #921 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.06% | #145 of 263 |
Weight: Xeris Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xeris Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xeris Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.64x
Xeris Pharmaceuticals Inc's market cap is 4.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2443.30x
Xeris Pharmaceuticals Inc's market cap is 2443.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.93 Billion | $2.46 Million | -$60.08 Million | 1189.18x | N/A |
| 2019 | $1.22 Billion | $2.72 Million | -$125.58 Million | 446.60x | N/A |
| 2020 | $848.36 Million | $2.72 Million | -$125.58 Million | 311.67x | N/A |
| 2021 | $505.22 Million | $49.59 Million | -$122.72 Million | 10.19x | N/A |
| 2022 | $229.33 Million | $110.25 Million | -$94.66 Million | 2.08x | N/A |
| 2023 | $405.21 Million | $163.91 Million | -$62.26 Million | 2.47x | N/A |
| 2024 | $584.54 Million | $203.07 Million | -$54.84 Million | 2.88x | N/A |
| 2025 | $1.35 Billion | $291.85 Million | $554.00K | 4.64x | 2443.30x |
Competitor Companies of XERS by Market Capitalization
Companies near Xeris Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Xeris Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Xeris Pharmaceuticals Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Xeris Pharmaceuticals Inc's market cap moved from $2.93 Billion to $ 1.08 Billion, with a yearly change of -13.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.08 Billion | -20.00% |
| 2025 | $1.35 Billion | +131.56% |
| 2024 | $584.54 Million | +44.26% |
| 2023 | $405.21 Million | +76.69% |
| 2022 | $229.33 Million | -54.61% |
| 2021 | $505.22 Million | -40.45% |
| 2020 | $848.36 Million | -30.21% |
| 2019 | $1.22 Billion | -58.53% |
| 2018 | $2.93 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Xeris Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.04 Billion USD |
| MoneyControl | $1.04 Billion USD |
| MarketWatch | $1.04 Billion USD |
| marketcap.company | $1.04 Billion USD |
| Reuters | $1.04 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more